Introduction
============

Familial hypercholesterolemia (FH) is a common genetic disorder and if not recognized early and treated appropriately can lead to severe atherosclerosis and premature coronary artery disease (CHD).^[@r1],[@r2]^

The prevalence of FH varies greatly between different studies depending on clinical criteria used and/or genetic confirmation.^[@r3],[@r4]^ The most common clinical criteria used are the Dutch Lipid Clinic Network (DLCN)^[@r5]^ and the Simon Broome Registry criteria.^[@r2]^ These criteria are based on low-density lipoprotein cholesterol (LDL-C) levels of \> 4.9 mmol/L (\> 189.0 mg/dL), the presence of CHD in the patient or first-degree family member, and physical examination like tendon xanthoma or corneal arcus before the age of 40 years. FH is inherited as a monogenic mutation in the low-density lipoprotein receptor (LDLR), apolipoprotein-B (*Apo B*), or proprotein convertase subtilisin/kexin type 9 (*PCSK9*) genes.^[@r6]^ However, FH can also be inherited as a polygenic form from the contribution of several common LDL-C raising single nucleotide variants.^[@r7]^

Our study aimed to describe the clinical and genetic characteristics of FH in patients presented to the lipid clinic at Sultan Qaboos University Hospital (SQUH), Muscat, Oman.

Methods
=======

SQUH is a tertiary hospital, and its lipid clinic is considered a referral center for FH patients across the country. In this study, a total of 450 patients who presented with high LDL-C (\>189.0 mg/dL or 4.9 mmol/L) were recruited. The patients were stratified according to the DLCN criteria.^[@r5]^ As per the DLCN criteria, the diagnosis of FH was derived from scores from several criteria, including clinical and family history, physical examination, baseline cholesterol levels, and molecular testing. A 'probable/definite' FH was considered when the DLCN score was 6 or higher, and a 'possible' FH was made when the DLCN score was 3 to 5. Those with DLCN scores of \< 3 were classified as 'unlikely' FH. Data collection included patients' demographics, clinical history, physical examination, biochemical and radiological investigations as well as genetic analysis. The study was approved by the Sultan Qaboos University, College of Medicine and Health Science's ethics committee (Reference: SQU-EC/172/18). All patients were required to sign informedconsent forms.

Descriptive statistics were used to describe the data. For categorical variables, frequencies and percentages were reported. Differences between groups were analyzed using Pearson's chi-squared tests (or Fisher's exact tests for expected cells \< 5). For continuous variables, mean and standard deviation were used to summarize the data while analysis was performed using ordinary least squares regression. An a priori two-tailed level of significance was set at the 0.05 level. Statistical analyses were conducted using STATA version 13.1 (STATA Corporation, College Station, TX, USA).

Results
=======

The overall mean age of the cohort was 48.0±12.0 years, 56.0% (n = 252) were males and 11.3%  (n = 51) were smokers. The proportion of patients with premature CHD, family history of FH, hypertension, and diabetes mellitus were 22.4% (n = 101), 99.6% (n = 448), 26.0% (n = 117), and 17.3% (n = 78), respectively. A total of 17.3% (n = 78) of the patients had percutaneous coronary intervention, 46.7% (n = 210) had high statin intensity therapy while 20.2% (n = 91) had statin and ezetimibe combination.

[Table 1](#t1){ref-type="table"} shows demographic, clinical, and statin characteristics of the patients according to DLCN criteria. The proportion of 'probable/definite', 'possible', and 'unlikely' FH were 27.6% (n = 124), 70.0% (n = 315), and 2.4% (n = 11), respectively. Compared to the 'unlikely' FH cohort, the 'probable/definite' FH group more likely to be associated with confirmed mutations (33.9% vs. 0.0; *p* \< 0.001), tendon xanthomas (25.0% vs 0.0; *p* \< 0.001), arcus corneal (36.3% vs 9.1%; *p* \< 0.001), coronary artery bypass graft (10.5% vs. 0.0; *p =* 0.008), high-intensity statin therapy (75.8% vs. 54.5%; *p* \< 0.001), and statin ezetimibe combination (50.8% vs. 27.3%; *p* \< 0.001). Furthermore, those with very high atherosclerotic vascular disease (ASCVD) risk were also associated with high-intensity statin therapy (55% vs. 43%; *p =* 0.006) and statin ezetimibe combination (26% vs. 17%; *p =* 0.023) \[[Table 2](#t2){ref-type="table"}\].

###### Demographic and clinical characteristics of Oman familial hypercholesterolemia (FH) cohort stratified by the Dutch Lipid Clinic Network (DLCN) criteria.

  -----------------------------------------------------------------------------------------------------
  Characteristics                   All\          DLCN criteria   p-value                    
                                    (n = 450)\                                               
                                    n (%)                                                    
  --------------------------------- ------------- --------------- ------------- ------------ ----------
  Demographic                                                                                

  Age, years, mean ± SD             48.0 ± 12.0   41.0 ± 15.0     49.0 ± 12.0   44.0±13.0    \< 0.001

  Male gender                       252 (56.0)    7 (63.6)        177 (56.2)    68 (54.8)    0.847

  Smoking                           51 (11.3)     0 (0.0)         45 (14.3)     6 (4.8)      0.039

  Medical history                                                                            

  History of FH                     448 (99.6)    11 (100)        314 (99.7)    123 (99.2)   0.510

  Genetic testing                   72 (16.0)     0 (0.0)         15 (4.8)      57 (46.0)    \< 0.001

  Confirmed mutation\*              42 (58.3)     0 (0.0)         0 (0.0)       42 (33.9)    \< 0.001

  Tendon xanthomas                  31 (6.9)      0 (0.0)         0 (0.0)       31 (25.0)    \< 0.001

  Arcus corneal                     65 (14.4)     1 (9.1)         19 (6.0)      45 (36.3)    \< 0.001

  Diabetes mellitus                 78 (17.3)     0 (0.0)         57 (18.1)     21 (16.9)    0.432

  Hypertension                      117 (26.0)    1 (9.1)         89 (28.3)     27 (21.8)    0.228

  Hx of premature CAD               101 (22.4)    3 (27.3)        59 (18.7)     39 (31.5)    0.041

  Angina                            54 (12.0)     1 (9.1)         36 (11.4)     17 (13.7)    0.628

  Myocardial infarction             55 (12.2)     2 (18.2)        35 (11.1)     18 (14.5)    0.650

  Hx of premature CBVD              14 (3.1)      1 (9.1)         8 (2.5)       5 (4.0)      0.428

  Hx of premature PAD               3 (0.7)       0 (0.0)         2 (0.6)       1 (0.8)      0.479

  Procedures and investigations                                                              

  PCI                               78 (17.3)     2 (18.2)        48 (15.2)     28 (22.6)    0.229

  CABG                              21 (4.7)      0 (.0.)         8 (2.5)       13 (10.5)    0.008

  Hx of CT angiogram                30 (6.7)      1 (9.1)         13 (4.1)      16 (12.9)    0.012

  Hx of CT coronary calcium score   35 (7.8)      0 (0.0)         16 (5.1)      19 (15.3)    0.007

  Hx of echocardiography,           91 (20.2)     1 (9.1)         66 (21.0)     24 (19.4)    0.881

  Hx of carotid doppler             3 (0.7)       0 (0.0)         0 (0.0)       3 (2.4)      0.086

  Statin therapy\*\*                                                                         

  Low-intensity statin therapy      56 (12.4)     3 (27.3)        49 (15.6)     4 (3.2)      

  Medium-intensity statin therapy   184 (40.9)    2 (18.2)        156 (49.5)    26 (21.0)    \< 0.001

  High-intensity statin therapy     210 (46.7)    6 (54.5)        110 (34.9)    94 (75.8)    

  Statin+ezitimibe combination      91 (20.2)     3 (27.3)        25 (7.9)      63 (50.8)    \< 0.001
  -----------------------------------------------------------------------------------------------------

SD: standard deviation; Hx: history; CAD: coronary artery disease; CBVD: cerebrovascular disease; PAD: peripheral artery disease; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; CT: computed tomography.

Percentages might not add to 100% due to rounding off.

\*Out of the 16.0% (72/450) that had genetic testing, 58.3% (42/72) had low-density lipoprotein receptor mutation.

\*\*High-intensity statin therapy was defined as those on atorvastatin 40--80 mg and rosuvastatin 20--40 mg, while medium-intensity statin therapy was defined as those on atorvastatin 10--20 mg, rosuvastatin 5--10 mg, simvastatin 20--40 mg, and pravastatin 40--80 mg. There were no patients on fluvastatin or lovastatin.

###### Statin therapy stratified by atherosclerotic vascular disease (ASCVD) risk.

  ------------------------------------------------------------------------------------------------
  Statin therapy\*                  All, n(%)\   Very high\          High\               p-value
                                    (n = 450)    ASCVD risk, n(%)\   ASCVD risk, n(%)\   
                                                 (n = 148)           (n = 302)           
  --------------------------------- ------------ ------------------- ------------------- ---------
  Low-intensity statin therapy      56 (12.4)    9 (6.1)             47 (15.6)           0.006

  Medium-intensity statin therapy   184 (40.9)   58 (39.2)           126 (41.7)          

  High-intensity statin therapy     210 (46.7)   81 (54.7)           129 (42.7)          

  Statin+ezitimibe combination      91 (20.2)    39 (26.4)           52 (17.2)           0.023
  ------------------------------------------------------------------------------------------------

\*High-intensity statin therapy was defined as those patients on atorvastatin 40--80 mg and rosuvastatin 20--40 mg. Medium-intensity statin therapy was defined as those on atorvastatin 10--20 mg, rosuvastatin 5--10 mg, simvastatin 20--40 mg and pravastatin 40--80 mg. There were no patients on fluvastatin or lovastatin.

Lipid profiles of Omani FH patients stratified by the DLCN criteria are outlined in [Table 3](#t3){ref-type="table"}. All lipid fractions (total cholesterol (TC) and LDL-C) at baseline and post-index were significantly higher in the 'probable/definite' FH group compared to the 'unlikely' FH cohort (all *p*-values \< 0.001). When compared to the baseline period \[[Table 4](#t4){ref-type="table"}\], post-index lipid levels that included TC (5.4 vs. 8.1 mmol/L; *p* \< 0.001), LDL-C (3.5 vs. 6.2 mmol/L; *p* \< 0.001), and non high-density lipoprotein cholesterol (non HDL-C) (4.1 vs. 6.9 mmol/L; *p* \< 0.001) were significantly lower in not only the high ASCVD risk but also very high ASCVD risk TC (5.3 vs. 8.2 mmol/L; *p* \< 0.001), LDL-C (3.3 vs. 6.3 mmol/L; *p* \< 0.001), and non HDL-C (4.2 vs. 7.0 mmol/L; *p* \< 0.001).

###### Lipid profiles of Omani familial hypercholesterolemia cohort stratified by the Dutch Lipid Clinic Network (DLCN) criteria.

  ------------------------------------------------------------------------------
  Characteristic      All\        DLCN        *p*-value               
                      (N = 450)                                       
  ------------------- ----------- ----------- ----------- ----------- ----------
  Total cholesterol                                                   

  Baseline            8.0 ± 1.4   6.8 ± 0.1   7.6 ± 0.8   9.2 ± 1.9   \< 0.001

  Post-index          5.3 ± 1.4   4.2 ± 1.0   5.1 ± 1.2   5.8 ± 1.8   \< 0.001

  LDL-cholesterol                                                     

  Baseline            6.1 ± 1.3   4.9 ± 0.0   5.7 ± 0.7   7.4 ± 1.8   \< 0.001

  Post-index          3.4 ± 1.3   2.3 ± 0.7   3.2 ± 1.1   3.4 ± 1.3   \< 0.001
  ------------------------------------------------------------------------------

Data are given as mean ± standard deviation.

LDL: low-density lipoprotein.

###### Lipid profiles of Omani familial hypercholesterolemia patients stratified by the atherosclerotic vascular disease risk status.

  --------------------------------------------------------------
  Characteristics,\          Baseline    Post-index   p-value
  mean ± SD, mmol/L                                   
  -------------------------- ----------- ------------ ----------
  Total cholesterol                                   

  All (n = 329)              8.1 ± 1.4   5.4 ± 1.5    \< 0.001

  High risk (n = 216)        8.1 ± 1.3   5.4 ± 1.3    \< 0.001

  Very high risk (n = 113)   8.2 ± 1.6   5.3 ± 1.7    \< 0.001

  LDL-cholesterol                                     

  All (n = 331)              6.3 ± 1.4   3.4 ± 1.3    \< 0.001

  High risk (n = 217)        6.2 ± 1.3   3.5 ± 1.3    \< 0.001

  Very high risk (n = 114)   6.3 ± 1.6   3.3 ± 1.3    \< 0.001

  Non-HDL-cholesterol                                 

  All (n = 320)              6.9 ± 1.4   4.1 ± 1.5    \< 0.001

  High risk (n = 213)        6.9 ± 1.4   4.1 ± 1.4    \< 0.001

  Very high risk (n = 107)   7.0 ± 1.6   4.2 ± 1.7    \< 0.001
  --------------------------------------------------------------

SD: standard deviation; LDL: low-density lipoprotein; HDL: high-density lipoprotein.

At baseline, 415 patients had populated lipid profiles while at follow-up 366 patients had their lipid levels documented.

[Figure 1](#f1){ref-type="fig"} represents LDL-C goal attainment at admission stratified by the DLCN and ASCVD criteria, respectively. Patients with 'probable/definite' FH were less likely to achieve their LDL-C goal attainment compared to those with 'unlikely' FH (13.0% vs. 57.1%; *p* \< 0.001). Those with very high ASCVD risk were less likely to their LDL-C goals compared to the high ASCVD risk cohort (9.6% vs. 32.0%; *p* \< 0.001).

![Low-density lipoprotein cholesterol goal attainment of the cohort stratified by DLNC and ASCVD risk.](OMJ-35-03-2000057-f1){#f1}

Discussion
==========

This paper describes the clinical and the genetic characteristics of patients referred to the lipid clinic at SQUH as a suspected case of FH. Patients were stratified according to the DLCN, with 27.6% patients diagnosed as 'probable/definite' FH, 70.0% as 'possible' FH, and 2.4% as the 'unlikely' FH group. There are few case reports about FH and its genetic characteristics in Oman.^[@r8]-[@r13]^ Currently, most suspected FH cases are referred to SQUH lipid clinic for genetic confirmation and advanced management.

FH remains underdiagnosed worldwide.^[@r14]^ There are no wide national registries for FH in Oman. The \"Oman cascade screening to prevent early onset risk of cardiovascular diseases in FH Young children and adult index cases and their families (OMANORYX) study\"^[@r15]^ is an ongoing study aimed to initiate early detection and treatment of FH in Oman through detection of index cases and cascade screening of first- and second-degree relatives to prevent CVD outcomes. The Gulf Familial Hypercholesterolemia Registry (Gulf FH)^[@r8]^ was a cross-sectional and prospective study to determine the FH prevalence, genetic characteristics, and current management in the adult patients living in the Arabian Gulf region. The prevalence of FH (based on both probable and possible FH) was 0.96%, 1/104 (332/34 366). In Oman, the expected number of FH patients according to the Gulf FH registry^[@r9]^ prevalence of 1/104 and the Omani population of 2 994 601 (based on the 2019 census^[@r16]^) is around 28 794 patients. This indicates a significant gap in the diagnosis of FH in Oman, and the OMANORYX study may help to decrease this gap. Nonetheless, there is a definite need to engage local health care authorities to establish quality improvement programs, policies, and centers like lipid clinics for FH screening, diagnosis, and management.^[@r15]^

FH remains undertreated worldwide.^[@r9],[@r14],[@r17]^ In the SAFEHEART Registry,^[@r17]^ only 11% of the FH patients reached their target goal of \< 2.6 mmol/L despite being on maximum lipid-lowering treatments. In our study, the overall goal attainment of LDL-C \< 2.6 mmol/L was achieved in 24.0% (data is not shown) of patients while only 10.0% of FH patients with very high risk and LDL-C goal of \< 1.8 mmol/L was achieved. High-intensity statins were prescribed in only 46.7% of patients, and 20.2% of patients were on both statins and ezetimibe.

Lipoprotein apheresis^[@r10]^ is only available at SQUH in Oman, and patients across the country are being referred to our center for the treatment of homozygous and severe heterozygous FH patients who do not respond to the maximum tolerated lipid-lowering treatments.

The Oman Society for Lipid and Atherosclerosis with support from the International Atherosclerosis Society has established an educational program like the 'Lipid Metabolism and Cardiovascular Risk' and 'Severe FH' courses^[@r18]^ to improve the knowledge and the management of various lipid disorders and FH in the Middle East and North Africa (MENA) region. Moreover, there are consensus clinical recommendations for the management of FH in the region.^[@r19],[@r20]^

Although molecular testing of FH is considered as a confirmatory step in the diagnosis and important to screen the family members of the index cases, it is still not widely available worldwide, and few centers perform them in the MENA region.^[@r21]^ In Oman, molecular testing for FH is performed in the biochemistry laboratory at SQUH.^[@r11]-[@r13]^ The genetic test is only performed in 16.0% of suspected cases due to limited resources. As expected, the mutation was confirmed in the 'probable/definitive' FH group (33.9%), and the most common type of mutation was the LDLR mutation. A total of 58.3% of the suspected cases were reported to have causative FH mutation. The rest of the cases were more likely to have a polygenic form of hypercholesterolemia.

Conclusion
==========

FH in Oman is still underdiagnosed and undertreated. Despite the use of high-intensity statin and combination therapies, a significant number of high and very ASCVD FH patients did not reach the LDL-C therapeutic goals. This implies the high need to engage the local health care authorities to set recommendations and quality improvement programs and policies for FH screening, diagnosis, and aggressive management.
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